FPT-CORPORATION
As part of its ongoing commitment to the highest standards of sustainable development, FPT Corporation (FPT) has published its ESG report and prioritized ESG as a key aspect of its 2024 development strategy. The report highlights FPT’s achievement of 87% positive employee feedback, certified by Great Place to Work® - a significantly higher rating than a typical global company’s average of 53%. The Corporation is also certified among Vietnam's Top 10 Best Large-Scale Workplaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415745348/en/
Happy Run race is one of FPT’s social responsibility activities (Photo: Business Wire)
“In 2023, I described FPT as a joyful sanctuary. I delineated the concept wherein FPT assumed the role of building a happier future for shareholders, customers, and employees. This depiction has begun to manifest itself into reality,” said FPT Chairman Dr. Truong Gia Binh.
FPT’s ESG commitment is reflected in four key areas: Work Environment, Environmental Sustainability, Social Responsibility, and Excellent Governance, with actions taking references from Global Reporting Initiative (GRI) Standards and 17 Sustainable Development Goals of the United Nations.
Building on the core values of "Respect - Innovation - Cohesion - Equality - Exemplarity - Lucidity," FPT is committed to creating a happy, diverse, and inclusive workplace. The Corporation has employees from 73 nationalities, with women representing 37.4% of the total workforce and 36.1% of managerial roles.
In 2023, the number of foreign employees at FPT increased by 67% year-on-year to 2,925, including senior-level members from such companies as Airbus, SCSK, Tata Consultancy Services, and HCL. FPT also recorded a decade-low turnover rate of 10.3% and a 13.6% increase in the total workforce compared to 2022. “We prioritize building a cohesive, family-like atmosphere where leaders and employees regard one another as family. In times of adversity, we stand together and never leave anyone behind,” FPT Chairman Dr. Truong Gia Binh added.
Social responsibility forms an integral part of FPT's culture. In 2023, FPT donated VND 205.2 billion (approximately $8.2 million) to social responsibility activities, benefiting over 83,753 people in Vietnam. The company's first global Happy Run race attracted 191,000 participants, raising VND 3.6 billion (approximately $145,000) to build schools in remote areas. Hope School - FPT’s initiative to support children orphaned by COVID-19 - has continued to ensure a safe and comprehensive learning environment for 230 students from 41 provinces, with a new construction set to be completed in 2024.
The Corporation also demonstrates its strong commitment to environmental conservation and the ambitious goal of becoming the pioneering company in Vietnam to achieve Net Zero emissions by 2040. FPT has been applying various measures to minimize environmental impact by reducing energy consumption and greenhouse gas emissions, such as monitoring 100% of energy usage data and replacing 100% of office waste bags with recyclable materials, while ensuring all employees receive annual training on environmental protection policy.
Regarding corporate governance, FPT pledges to build and maintain a governance framework including charter, regulations, process handbooks, and regulatory documents across the Corporation to ensure a professional, effective and disciplined governance system from the Corporation to its subsidiaries.
Vertical functional management and centralized data management serve as the "backbone" of FPT's efforts to optimize its management and operations, as well as fostering sustainable growth. The Corporation also conducted internal digital transformation projects, with 42 being implemented in 2023 to ensure cost savings, optimize operations, and improve experience for both employees and customers.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com.vn/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415745348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
